OSCR

Immunotherapy with B28, an antibody to Aβ oligomers, potently decreases amyloid plaques, microgliosis, and memory decline in APP knock-in mice.

Overview

Authors: Ting Yang1,2,3, Yi Ran Xu1,2, Shaomin Li1, Jean-Pierre Bellier1, Youqi Tao1, Anna E. Francis1, Andrew M. Stern1, Shanxue Jin1, Beth L. Ostaszewski1, Trebor L. Lawton4, Laurent Pradier5, David Reczek6, Cynthia A. Lemere1, Dominic M. Walsh1, Dennis J. Selkoe1
ORCID iDs: Dennis J. Selkoe
  1. Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, 60 Fenwood Road, Boston, MA 02115, USA
  2. These authors contributed equally
  3. Lead contact
  4. Abyssinia Biologics, Inc, 855 Boylston Street, #1000, Boston, MA 02116, USA
  5. Sanofi Neurodegenerative Research, Chilly Mazarin, France
  6. Sanofi US Large Molecule Research, 350 Water St, Cambridge, MA 02141, USA
Institutions: Brigham and Women's Hospital (United States); Harvard University (United States); Sanofi (France) (France)
Journal: Cell reports, volume 45, issue 7, article 117599
Dates: published online 30 June 2026; in print 28 July 2026
Type: Research article · Language: English
License: CC BY-NC
Identifiers: DOI 10.1016/j.celrep.2026.117599 · PMID 42378088 · PMCID PMC13533279 · OpenAlex W7166647214
Open access: gold, a free copy (OpenAlex)
Status: code on request
Categories: human (organism), mouse (organism), Alzheimer's / dementia (population), cellular / molecular (subfield)
Methods: Statistics, Smoothing, state filtering, decompositions
Keywords: Immunotherapy, Alzheimer’s disease, AD, Mouse Model, Aβ, Amyloid Β-protein, Cp: Neuroscience
MeSH: Alzheimer Disease*, Amyloid beta-Peptides*, Amyloid beta-Protein Precursor*, Gliosis*, Immunotherapy*, Memory Disorders*, Microglia*, Plaque, Amyloid*, Animals, Brain, Disease Models, Animal, Gene Knock-In Techniques, Humans, Mice, Mice, Transgenic (* major topic)
Topic: Alzheimer's disease research and treatments (Physiology, Medicine), according to OpenAlex
Funding: Foundation for the National Institutes of Health (P01AG015379); NIA NIH HHS (P01 AG015379, R01 AG006173, RF1 AG006173); National Institutes of Health (RF1AG006173, R01NS136122, P01AG015379); NINDS NIH HHS (R01 NS136122)
Citations: not cited yet (Europe PMC); 65 references in the paper
Research resources: CD68 RRID:AB_10975465, RRID:AB_162542, IBA1 RRID:AB_2224402, NeuN RRID:AB_2532109, RRID:AB_2534017, RRID:AB_2534102, RRID:AB_2782998

Abstract

Immunotherapy against amyloid β-protein (Aβ) for Alzheimer’s disease (AD) has been widely approved. Breakthrough disease-modifying treatments such as lecanemab and donanemab are often followed by drugs with improved efficacy. By immunizing Trianni mice with aggregated synthetic Aβ, we obtained B28, a fully human antibody specifically selected for its neutralization of tau neuritic dystrophy induced by AD brain-derived oligomers. In a blinded trial in mutant human APPNL-G-F knock-in mice, weekly infusions of B28 for four months markedly reduced both amyloid plaques and Aβ oligomers, attenuated plaque-associated astrocytosis and microgliosis, preserved neurons, and lessened memory decline. Biochemical and histological analyses showed that B28 engaged both plaque-bound and diffusible Aβ, forming immune complexes and depleting free Aβ. In in vitro immunoassays, B28 had significantly higher affinity and captured more Aβ from AD brain extracts than did lecanemab. B28 is a potent, aggregate-preferring Aβ antibody that clears plaques and decreases gliosis, supporting its clinical development.

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

No dataset and no data link were found in the paper.

Data and code availability

Data reported in this paper will be shared by the lead contact upon request.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

This paper does not report original code.

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 2, 28 September 2026

  • Publisher: n/a → Cell Press
  • Authors: added Dennis J. Selkoe (0000-0001-8846-9767); removed Dennis J. Selkoe

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 15 authors, 7 keywords, 15 MeSH terms, 4 funders, 64 references, 7 RRIDs.

Cite

This paper

Yang, T., Xu, Y. R., Li, S., Bellier, J.-P., Tao, Y., Francis, A. E., Stern, A. M., Jin, S., Ostaszewski, B. L., Lawton, T. L., Pradier, L., Reczek, D., Lemere, C. A., Walsh, D. M., & Selkoe, D. J. (2026). Immunotherapy with B28, an antibody to Aβ oligomers, potently decreases amyloid plaques, microgliosis, and memory decline in APP knock-in mice. Cell reports, 45(7), 117599. https://doi.org/10.1016/j.celrep.2026.117599

BibTeX

@article{yang2026immunotherapy,
author = {Yang, Ting and Xu, Yi Ran and Li, Shaomin and Bellier, Jean-Pierre and Tao, Youqi and Francis, Anna E. and Stern, Andrew M. and Jin, Shanxue and Ostaszewski, Beth L. and Lawton, Trebor L. and Pradier, Laurent and Reczek, David and Lemere, Cynthia A. and Walsh, Dominic M. and Selkoe, Dennis J.},
title = {{Immunotherapy with B28, an antibody to Aβ oligomers, potently decreases amyloid plaques, microgliosis, and memory decline in APP knock-in mice}},
journal = {Cell reports},
year = {2026},
month = jun,
volume = {45},
number = {7},
pages = {117599},
publisher = {Cell Press},
issn = {2211-1247},
doi = {10.1016/j.celrep.2026.117599},
url = {https://doi.org/10.1016/j.celrep.2026.117599},
pmid = {42378088},
pmcid = {PMC13533279}
}

RIS

TY - JOUR
AU - Yang, Ting
AU - Xu, Yi Ran
AU - Li, Shaomin
AU - Bellier, Jean-Pierre
AU - Tao, Youqi
AU - Francis, Anna E.
AU - Stern, Andrew M.
AU - Jin, Shanxue
AU - Ostaszewski, Beth L.
AU - Lawton, Trebor L.
AU - Pradier, Laurent
AU - Reczek, David
AU - Lemere, Cynthia A.
AU - Walsh, Dominic M.
AU - Selkoe, Dennis J.
TI - Immunotherapy with B28, an antibody to Aβ oligomers, potently decreases amyloid plaques, microgliosis, and memory decline in APP knock-in mice
T2 - Cell reports
J2 - Cell Rep
PY - 2026
DA - 2026/06/30
VL - 45
IS - 7
SP - 117599
SN - 2211-1247
PB - Cell Press
DO - 10.1016/j.celrep.2026.117599
UR - https://doi.org/10.1016/j.celrep.2026.117599
LA - en
ER -

CSL-JSON

{
"id": "10.1016/j.celrep.2026.117599",
"type": "article-journal",
"title": "Immunotherapy with B28, an antibody to Aβ oligomers, potently decreases amyloid plaques, microgliosis, and memory decline in APP knock-in mice",
"container-title": "Cell reports",
"author": [
{
"family": "Yang",
"given": "Ting"
},
{
"family": "Xu",
"given": "Yi Ran"
},
{
"family": "Li",
"given": "Shaomin"
},
{
"family": "Bellier",
"given": "Jean-Pierre"
},
{
"family": "Tao",
"given": "Youqi"
},
{
"family": "Francis",
"given": "Anna E."
},
{
"family": "Stern",
"given": "Andrew M."
},
{
"family": "Jin",
"given": "Shanxue"
},
{
"family": "Ostaszewski",
"given": "Beth L."
},
{
"family": "Lawton",
"given": "Trebor L."
},
{
"family": "Pradier",
"given": "Laurent"
},
{
"family": "Reczek",
"given": "David"
},
{
"family": "Lemere",
"given": "Cynthia A."
},
{
"family": "Walsh",
"given": "Dominic M."
},
{
"family": "Selkoe",
"given": "Dennis J."
}
],
"container-title-short": "Cell Rep",
"volume": "45",
"issue": "7",
"page": "117599",
"DOI": "10.1016/j.celrep.2026.117599",
"PMID": "42378088",
"PMCID": "PMC13533279",
"ISSN": "2211-1247",
"publisher": "Cell Press",
"URL": "https://doi.org/10.1016/j.celrep.2026.117599",
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
30
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1186/s13024-026-00965-x
Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice.
Journal: Molecular neurodegeneration
In common: Alzheimer's / dementia, mouse, cellular / molecular, 6 references
[2] doi:10.1038/s41467-026-75895-9
Distinct Filament Conformation for Receptor-Bound Amyloid-β from Alzheimer's Disease Brain.
Journal: Nature communications
In common: Alzheimer's / dementia, cellular / molecular, 5 references
[3] doi:10.1016/j.celrep.2026.117505 [code]
Impaired spatial coding and neuronal hyperactivity in the medial entorhinal cortex of aged APP knock-in mice.
Journal: Cell reports
In common: Alzheimer's / dementia, mouse, 3 references
[4] doi:10.3390/ijms27114756
Multi-Omics Integration and Causal Inference Identify HSD17B1 as a Potential Nobiletin Target Linking Neurosteroid Metabolism to Alzheimer's Disease.
Journal: International journal of molecular sciences
In common: Alzheimer's / dementia, cellular / molecular, 3 references
[5] doi:10.1186/s13024-026-00946-0
Insulin resistance alters cortical inhibitory neurons and microglia to exacerbate Alzheimer's knock-in mouse phenotypes.
Journal: Molecular neurodegeneration
In common: Alzheimer's / dementia, mouse, cellular / molecular, 2 references
[6] doi:10.1016/j.crmeth.2026.101418
Single-molecule detection methods to study alpha-synuclein aggregation in postmortem Parkinson's disease brains.
Journal: Cell reports methods
In common: mouse, cellular / molecular, 2 references
[7] doi:10.3389/fnagi.2026.1847611 [code]
APOE ε4-associated hippocampal atrophy trajectories across the Alzheimer's disease continuum: a systematic review, meta-analysis, and longitudinal validation.
Journal: Frontiers in aging neuroscience
In common: Alzheimer's / dementia, 3 references
[8] doi:10.26508/lsa.202603668
Differential A-to-I editing of SINE B2 RNAs unveils an epitranscriptome response to Aβ neurotoxicity.
Journal: Life science alliance
In common: Alzheimer's / dementia, mouse, 2 references
[9] doi:10.1186/s12974-026-03796-1 [code]
Tryptophan-kynurenine metabolic reprogramming along the gut-brain axis alleviates Alzheimer's pathology.
Journal: Journal of neuroinflammation
In common: Alzheimer's / dementia, mouse, cellular / molecular, 2 references
[10] doi:10.1002/alz.71337 [code]
Tracking tau and cellular responses in human iPSC-microglia: from uptake to seedable secretion, including in extracellular vesicles.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
In common: Alzheimer's / dementia, cellular / molecular, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.